Sanofi delivered solid growth in Q2 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Sanofi (SNY) Reports Q2 Loss of EUR0.07 on Revenues of EUR8.63B
July 29, 2019 5:58 AM EDTSanofi (NASDAQ: SNY) reported Q2 EPS of (EUR0.07). Revenue for the quarter came in at EUR8.63 billion.
Second-quarter 2019 sales growth(3) driven by Sanofi Genzyme, Sanofi Pasteur and Emerging Markets
Net sales were 8,628 million, up 5.5% on a reported basis, up 3.9%(3) at CER and up 5.8% at CER/CS(4).Sanofi Genzyme sales up 21.8% due to strong launch performance of Dupixent®.Vaccines sales increased 24.7% mainly reflecting the recovery and growth of Pentaxim® in China and low basis for comparison.CHC sales up 1.1%, as U.S. growth more than offset lower sales in Europe... More